taxifolin and Cystadenocarcinoma, Serous

taxifolin has been researched along with Cystadenocarcinoma, Serous in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bast, A; Boven, E; Grimbergen, JA; Kramer, K; Kuiper, K; van Acker, SA; van den Berg, DJ; van der Vijgh, WJ1

Other Studies

1 other study(ies) available for taxifolin and Cystadenocarcinoma, Serous

ArticleYear
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Cardiomyopathies; Catechin; Chelation Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Electrocardiography; Female; Flavonoids; Flavonols; Free Radical Scavengers; Free Radicals; Humans; Hydroxyethylrutoside; Iron; Iron Chelating Agents; Kaempferols; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Ovarian Neoplasms; Quercetin; Razoxane; Rutin; Telemetry; Tumor Cells, Cultured; Weight Loss

1997